Monkeypox Update: Vaccine shortage, sewage surveillance and global testing
As concern over the monkeypox outbreak continues to rise, we take a look at major developments from the first week of August.
More than 80 countries where monkeypox is not endemic have reported outbreaks of the viral disease, which the World Health Organisation has declared a global health emergency. Confirmed cases have crossed 27,800 and non-endemic countries Brazil, India and Spain have reported their first deaths from the virus.
Vaccine shortage
On Tuesday, US health officials authorised a plan to stretch out the country’s limited supply of monkeypox vaccine by giving people just one-fifth of the usual dose. The dose-sparing approach calls for intradermal injection of the Jynneos (also known as Imvanex) vaccine just under the skin instead of a full dose into the underlying fat — a practice that may improve immune response. Recipients would still get two shots spaced four weeks apart.
This unusual measure is being taken to supplement the country’s shortfall in vaccine doses. Currently, the US has just 440,000 doses available, which increases to 2 million if the dose-sparing method is used.
Robert Fenton, the White House’s monkeypox response coordinator, told reporters: ‘It’s safe, it’s effective, and it will significantly scale the volume of vaccine doses available for communities across the country.’
European officials are now considering whether to follow suit, given spiraling case numbers on the continent. Speaking to Reuters, a spokesperson for the European Medicines Agency said the agency would ‘discuss the approach’ with Bavarian Nordic, who makes the vaccine, as well as individual member states.
Sewage surveillance
A team of researchers who used wastewater surveillance to track the incidence of COVID-19 is now turning their attention to monkeypox.
Surveillance and testing of sewage water has long held promise for the early detection of health threats but had limited applications before the COVID pandemic. In the US, such risk monitoring was largely confined to academic projects.
When COVID-19 emerged, a research group made up of scientists at Stanford University, the University of Michigan, and Emory University pioneered efforts to recalibrate surveillance techniques for detection of the virus, marking the first time that wastewater has been used to track a respiratory disease.
This research team, the Sewer Coronavirus Alert Network, is now expanding wastewater monitoring to detect monkeypox in the US.
Test kits
SaaS company WeTrade Group has struck a strategic partnership with Jiqing Biomedical Technology to produce monkeypox virus test kits and antigen tests.
Jiqing, a Chinese biotech focused on medical research and experimental development, created an antigen self-test kit for COVID-19 which was granted EU approval. With the emergence and spread of monkeypox, Jiqing developed a nucleic acid RT-LAMP test and a colloidal gold technique antigen test.
Working with Jiqing, WeTrade Group will leverage its digital tools to rapidly bring monkeypox virus test kits to market with the power of YCloud, a cloud intelligent system for microbusinesses, and its industry accumulation in computer technology and big data.
Therapeutics
SIGA Technologies confirmed this week that it will deliver $26 million worth of an intravenous formulation of smallpox drug TPOXX to the United States in 2023, after the US government elected to exercise certain procurement options.
Oral and intravenous formulations of TPOXX are approved by the US FDA for the treatment of smallpox, but not yet monkeypox. However, the US CDC provided guidance for its use under expanded access as an investigational drug.
The IV treatment will be a vital option for patients unable to swallow the oral pill as monkeypox symptoms include rashes and blisters in the mouth.
For more information on the global monkeypox response, read our recent feature: Vaccine industry must help fight monkeypox and secure supply chains
Related News
-
News How to disrupt an industry as big as pharma for the better?
In this interview, hear from Matthew Wise, Head of Data at CCD Partners, on the companies they've been looking into that are offering new and interesting perspectives that have the potential to shake up the pharmaceutical industry, and how they'... -
News CPHI Pharma Awards 2024: Meet the winners from the CPHI Celebration
This year we had a lot to celebrate, the 35th Anniversary of CPHI, and our esteemed award winners, of which we included two additional categories this year, the Future Leader award, and Woman of the Year award. -
News CPHI Milan 2024 - From the Floor
Milan and CPHI welcome you to 2024 CPHI Milan! As we celebrate the 35th edition of our flagship CPHI show, editors Vivian Xie and Lucy Chard bring you the latest from the show floor, conference sessions, and innovative solutions from all exhibitors, at... -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News A Day in the Life of a Global CDMO Chapter Lead – Manufacturing
The 'Day in the Life of' series has covered many aspects of the pharmaceutical pipeline, including R&D and procurement, now we're taking a look at manufacturing from a global CDMO perspective. -
News Eisai Alzheimer’s drug authorised in UK but still faces obstacles
In partnership with BioArctic AB, pharmaceutical company Eisai has been granted Marketing Authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) for its Alzheimer’s disease drug product Leqembi. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance